AI-designed universal vaccine clears first human trial, targets future coronavirus threats with needle-free delivery

Article excerpt

A universal coronavirus vaccine designed with AI has successfully completed its first human trial, showing it is safe with no significant side effects. Developed by the University of Cambridge and spin-out company DIOSynVax, the vaccine targets a broad range of Sarbecovirus threats, potentially offering protection against future coronavirus outbreaks beyond COVID-19. The developers are exploring needle-free delivery methods, which could simplify vaccination campaigns and improve global uptake. The trial represents a significant step toward preventive vaccines that could protect against multiple coronavirus variants and species simultaneously, rather than requiring strain-specific boosters.